Newsletter - March 29, 2018
Limitations of Sunshine: Disclosure Laws Do Little to Discourage Undesirable Activities
It is assumed that greater transparency would discourage undesirable activities but experience shows that the disclosing parties become more careful and use reporting loopholes to their advantage. A review of the California law that requires companies...Read More
FDA Strongly Opposes Compounding Drugs for Financial Reasons
In its latest Guidance Document and announcement for the current policy for compounding pharmacies, FDA emphasizes that the law supports only compounding drugs for which there is a clearly defined “clinical need” and not where compounded versions of approved drugs are created to make cheaper treatments for patients....Read More
Limitations of Sunshine: Disclosure Laws Do Little to Discourage Undesirable Activities
It is assumed that greater transparency would discourage undesirable activities but experience shows that the disclosing parties become more careful and use reporting loopholes to their advantage. A review of the California law that requires companies...Read More
FDA Strongly Opposes Compounding Drugs for Financial Reasons
In its latest Guidance Document and announcement for the current policy for compounding pharmacies, FDA emphasizes that the law supports only compounding drugs for which there is a clearly defined “clinical need” and not where compounded versions of approved drugs are created to make cheaper treatments for patients....Read More
